Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · IEX Real-Time Price · USD
2.520
+0.020 (0.80%)
Apr 24, 2024, 11:56 AM EDT - Market open
Company Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States.
The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Alpha Tau Medical Ltd.
| Country | Israel |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Uzi Sofer |
Contact Details
Address: Kiryat Hamada 5 Jerusalem, L3 9777605 Israel | |
| Phone | 972-3-577-4115 |
| Website | alphatau.com |
Stock Details
| Ticker Symbol | DRTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001871321 |
| CUSIP Number | M0740A108 |
| ISIN Number | IL0011839383 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Uzi Sofer | Chief Executive Officer and Chairman |
| Raphi Levy | Chief Financial Officer |
| Amnon Gat | Chief Operations Officer |
| Peter M. Melnyk | Chief Commercial Officer |
| Dr. Robert B. Den M.D. | Chief Medical Officer and Member of Scientific Advisory Board |
| Ronen Segal | Chief Technology Officer |
| Prof. Yona Keisari | Chief Scientific Officer and Member of Scientific Advisory board |
| Rebecca Becker | Vice President of legal |
| Prof. Itzhak Kelson | Chief Physics Officer and Member of Scientific Advisory Board |
| Yael Zeiger | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2024 | 6-K | Report of foreign issuer |
| Mar 15, 2024 | 144 | Filing |
| Mar 7, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 7, 2024 | 6-K | Report of foreign issuer |
| Mar 7, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Feb 26, 2024 | 6-K | Report of foreign issuer |
| Dec 20, 2023 | 6-K | Report of foreign issuer |
| Dec 18, 2023 | 144 | Filing |
| Nov 29, 2023 | 6-K | Report of foreign issuer |
| Nov 28, 2023 | 6-K | Report of foreign issuer |